TScan Therapeutics will host a virtual event on December 8 to discuss ALLOHA Phase 1 trial data and future opportunities.
Quiver AI Summary
TScan Therapeutics, Inc. announced it will host a virtual event on December 8 to present updated data from its ALLOHA Phase 1 trial at the upcoming ASH Annual Meeting. The session will feature a detailed review of two-year relapse data from patients receiving the TCR-engineered T cell therapy TSC-101 for hematologic malignancies as they undergo allogeneic hematopoietic cell transplantation. The company will also discuss its new manufacturing process, which is expected to be used in a pivotal trial beginning in the second quarter of 2026, as well as the market potential for TSC-101 and its additional product candidates. Key speakers at the event include Dr. Ran Reshef from Columbia University and TScan's CEO, Gavin MacBeath. A replay of the event will be available on TScan’s website following the live presentation.
Potential Positives
- The upcoming virtual KOL event showcases updated data from the ALLOHA™ Phase 1 trial, highlighting the company's commitment to transparency and engagement with stakeholders.
- The event will reveal two-year relapse data on initial patients, which may provide significant insights into the effectiveness of TSC-101 for heme malignancies.
- The discussion of an improved commercial-ready manufacturing process signifies advancements in the company's operational capabilities, potentially enhancing future clinical trials.
- The focus on the unmet medical need and market opportunity for TSC-101 indicates the company's strategic planning for future growth in a vital therapeutic area.
Potential Negatives
- The announcement of a virtual KOL event suggests a need to clarify or generate interest regarding the trial's data and future market opportunities, which may indicate underlying concerns about the trial's progress or market reception.
- The upcoming pivotal trial is scheduled to start in the second quarter of 2026, indicating a potentially lengthy development timeline that could delay potential revenue generation.
- Discussion of relapse data from the Phase 1 trial could raise questions about the efficacy of TSC-101, particularly if the data are not favorable.
FAQ
What is the ALLOHA™ Phase 1 trial about?
The ALLOHA™ Phase 1 trial evaluates TSC-101 in patients with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation.
When will the KOL event take place?
The virtual key opinion leader event will occur on Monday, December 8, at 8:00 a.m. ET.
How can I register for the virtual event?
Registration for the event can be found on TScan Therapeutics' website.
What will be discussed at the KOL event?
The event will cover updated data from the ALLOHA Phase 1 trial and the market opportunity for TSC-101.
Where can I find the replay of the event?
The replay will be available in the "Events and Presentations" section of TScan's website.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$TCRX Hedge Fund Activity
We have seen 24 institutional investors add shares of $TCRX stock to their portfolio, and 73 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 3,500,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $5,075,000
- CHECKPOINT CAPITAL L.P. removed 2,017,650 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $2,925,592
- ECOR1 CAPITAL, LLC removed 662,833 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $961,107
- ABERDEEN GROUP PLC added 463,372 shares (+52.0%) to their portfolio in Q3 2025, for an estimated $843,337
- UBS GROUP AG removed 389,328 shares (-97.2%) from their portfolio in Q3 2025, for an estimated $708,576
- GOLDMAN SACHS GROUP INC removed 299,090 shares (-69.5%) from their portfolio in Q3 2025, for an estimated $544,343
- BLACKROCK, INC. removed 183,760 shares (-7.2%) from their portfolio in Q3 2025, for an estimated $334,443
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$TCRX Analyst Ratings
Wall Street analysts have issued reports on $TCRX in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 11/13/2025
- Needham issued a "Buy" rating on 11/04/2025
To track analyst ratings and price targets for $TCRX, check out Quiver Quantitative's $TCRX forecast page.
$TCRX Price Targets
Multiple analysts have issued price targets for $TCRX recently. We have seen 2 analysts offer price targets for $TCRX in the last 6 months, with a median target of $6.5.
Here are some recent targets:
- Andres Y. Maldonado from HC Wainwright & Co. set a target price of $7.0 on 11/13/2025
- Gil Blum from Needham set a target price of $6.0 on 11/04/2025
Full Release
WALTHAM, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the Company will host a virtual key opinion leader (KOL) event to discuss updated data from the ALLOHA™ Phase 1 trial being presented at the 67 th American Society of Hematology (ASH) Annual Meeting and Exposition and the future market opportunity for its heme program. The virtual event will take place on Monday, December 8, at 8:00 a.m. ET.
The event will provide an in-depth review of the poster presented at the ASH Annual Meeting, including two-year relapse data on initial patients from TScan’s ongoing ALLOHA Phase 1 trial evaluating TSC-101 in patients with heme malignancies undergoing allogeneic hematopoietic cell transplantation (HCT). The Company will discuss its improved commercial-ready manufacturing process that has recently been implemented in the ALLOHA Phase 1 trial and will be used in the upcoming pivotal trial scheduled to start in the second quarter of 2026. The Company will also review the unmet medical need and potential market opportunity for TSC-101 and follow-on product candidates.
Featured speakers include:
-
Ran Reshef, M.D., M.Sc., Director of Translational Research, Blood and Marrow Transplantation Program, Director of the Cell Therapy Program, Columbia University Irving Medical Center
-
Gavin MacBeath, Ph.D., Chief Executive Officer, TScan Therapeutics
-
Stephen Camiolo, Senior Vice President, Market Access, TScan Therapeutics
Registration for the live event can be found here . A replay will be made available on the “ Events and Presentations ” section of the Company’s website at ir.tscan.com .
About TScan Therapeutics, Inc.
TScan is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidate is in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation (the ALLOHA ™ Phase 1 heme trial). The Company has developed multiple TCR-T therapy candidates for solid tumors and is currently developing methods for in vivo engineering using these candidates. The Company is also applying their TargetScan platform to discover novel targets in various T cell-mediated autoimmune disorders.
Contacts
Troy Neubecker
TScan Therapeutics, Inc.
Investor Relations
857-399-9517
[email protected]
Melissa Forst
Argot Partners
212-600-1902
[email protected]
